CA9 and neoplasm: IS-[111In]In-DO2A-ALB1 markedly increased tumor uptake and decreased renal uptake compared with a control radioligand without ALB, demonstrating the effectiveness of a strategy to introduce ALB into CA-IX-targeted radioligands.